Free website hits

Good morning, everyone. Damian Garde here, filling in for Ed Silverman on the last work day of a holiday-shortened week. On that note, we’ll be taking off tomorrow and Friday in the name of Thanksgiving, so you won’t see your requisite menu of tidbits again until Monday. But first, here are this morning’s items of interest to get your day started.

Purdue Pharma, maker of OxyContin, pleaded guilty to three charges related to its role in the opioid epidemic that has led to hundreds of thousands of deaths, the Associated Press reports. The company admitted to misleading authorities and paying doctors to encourage prescribing OxyContin. The agreement includes $8.3 billion in penalties and forfeitures, but Purdue only has to hand over $225 million as long as it complies with a separate settlement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]